Ularitide
Also known as: CRD-100, INN: Ularitide, Synthetic urodilatin, Ularitide, Urodilatin (synthetic)
Source Ularitide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ularitide is a 40‑amino‑acid synthetic analogue of urodilatin used intravenously for acute decompensated heart failure, primarily approved in Japan.
Mechanism of Action
Activates natriuretic peptide receptor A (NPR‑A), increasing intracellular cGMP → vasodilation, natriuresis, diuresis and inhibition of the renin‑angiotensin‑aldosterone system.
Routes of Administration
Goals & Uses
- Acute decompensated heart failureCardiovascularModerate
- Natriuresis and diuresisFluid/electrolyte ManagementModerate
- Acute decompensated heart failure treatmentCardiovascularModerate
- Renal protection in heart failureRenalLow
- Systemic vasodilationHemodynamicModerate
- Reduction of cardiac filling pressuresHemodynamicModerate
- RAAS suppressionCardiovascular/EndocrineLow
Contraindications
- Systolic blood pressure < 90 mmHgHemodynamicHigh
- Cardiogenic shock or severe hypotensionCardiovascularHigh
- Known hypersensitivity to ularitideImmunologicHigh
- Severe renal impairment / anuriaRenalModerate
- Hypersensitivity to ularitide or natriuretic peptidesImmunologicalHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- Atrial fibrillationCardiovascularUncommon
- HypotensionCardiovascularCommonLow blood pressure
- Renal dysfunctionRenalRare
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Worsening renal functionRenalUncommon
Drug Interactions
- Loop diureticsLow
- Phosphodiesterase inhibitors (e.g., sildenafil)High
- ACE inhibitors / ARBsModerate
- Other vasodilators (e.g., nitroglycerin)Moderate
- Antihypertensives / vasodilatorsModerate
- DiureticsLowMay worsen dehydration or electrolyte imbalance
Population Constraints
- Pediatric patientsAgeRelative
- Elderly patients (≥75 years)AgeRelative
- Pregnant womenReproductiveRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization granted.
- United StatesInvestigationalPhase II/III trials ongoing for acute heart failure.
- United KingdomUnapprovedNot licensed.
Not approved by FDA, EMA, or other major regulatory agencies. Development largely discontinued following negative Phase III (TRUE-AHF) results in 2017. Investigated under IND in the US and clinical trial authorization in the EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ularitide?
Ularitide is a 40‑amino‑acid synthetic analogue of urodilatin used intravenously for acute decompensated heart failure, primarily approved in Japan.
What is Ularitide used for?
Ularitide is educationally associated with: Acute decompensated heart failure, Natriuresis and diuresis, Acute decompensated heart failure treatment, Renal protection in heart failure, Systemic vasodilation, Reduction of cardiac filling pressures, RAAS suppression. Educational only — not medical advice.
How is Ularitide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Ularitide?
Reported adverse effects include: Headache, Atrial fibrillation, Hypotension, Renal dysfunction, Nausea, Worsening renal function. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ularitide?
Recorded contraindications: Systolic blood pressure < 90 mmHg, Cardiogenic shock or severe hypotension, Known hypersensitivity to ularitide, Severe renal impairment / anuria, Hypersensitivity to ularitide or natriuretic peptides, Severe hypotension. Consult a qualified clinician before use.